Organogenesis makes regenerative medicine products for advanced wound care and surgical and sports medicine, sold to health care providers. ORGO reports earnings on Thu, Nov 5, 2026.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Aug 7 | Truist Securities | Target lowered | Hold | |
| May 28 | Truist Securities | Initiated | Hold |
Seasonality
How ORGO has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2017.
Whale Options Flow
90DNo whale options trades in ORGO in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ORGO is in one of them and how their past ORGO trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered ORGO in an article yet. Here's the latest on the wider market.
About Organogenesis Holdings
Organogenesis is a regenerative medicine company based in Canton, Massachusetts. It develops, manufactures, and sells products for advanced wound care, including treatments for chronic and acute wounds, and for surgical and sports medicine, such as soft tissue repair and open surgical wounds. Its customers include hospitals, wound care centers, ambulatory surgery centers, government facilities, and physician offices. The company is also developing ReNu, a candidate for knee osteoarthritis.
- Headquarters
- Canton, MA